Central retinal vein occlusion: A review

Clinical and Experimental Ophthalmology

Volumn 40, Issue 1, 2012, Pages 48-58

  Mcallister, Ian L ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Bevacizumab; Central retinal vein occlusion; Chorioretinal venous anastomosis; Laser; Ranibizumab

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BEVACIZUMAB; DEXAMETHASONE; FIBRINOLYTIC AGENT; FLUOCINOLONE ACETONIDE; PEGAPTANIB; RANIBIZUMAB; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR; TRIAMCINOLONE; TROXERUTIN;

ANASTOMOSIS; BYPASS SURGERY; CENTRAL RETINA ARTERY OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CLINICAL FEATURE; DECOMPRESSION; DRUG DOSE COMPARISON; HEMODILUTION; HISTORY; HUMAN; HYDROSTATIC PRESSURE; IMPLANT; INTRAOCULAR PRESSURE; LASER CHORIORETINAL ANASTOMOSIS; LASER COAGULATION; MEDICAL LITERATURE; NEODYMIUM LASER; OPTIC NERVE SHEATH DECOMPRESSION; PANRETINAL LASER PHOTOCOAGULATION; PATHOGENESIS; PREVALENCE; RADIAL OPTIC NEUROTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DETACHMENT; RETINA ISCHEMIA; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; REVIEW; RISK FACTOR; SIDE EFFECT; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE;

ANASTOMOSIS, SURGICAL; ANGIOGENESIS INHIBITORS; DECOMPRESSION, SURGICAL; HUMANS; LASER COAGULATION; RETINAL VEIN OCCLUSION; RISK FACTORS; VISION DISORDERS;

EID: 84856659352     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2011.02713.x     Document Type: Review

References (98)

1. Liebreich R. Ophthalmoskopishe Notizen: Ueber die Farbe des Augengrundes. Albrecht Von Graefes Arch Ophthalmol 1855; 1: 333-56.
2. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia: the Blue Mountain Eye Study. Arch Ophthalmol 1996; 114: 1243-7.
3. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000; 98: 133-41.
4. Rogers S, McIntosh RL, Cheung N etal. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117: 313-19.
5. McIntosh RL, Rogers SL, Lim L etal. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010; 117: 1113-23.
6. Hayreh SS. Classification of central retinal vein occlusion. Ophthalmology 1983; 90: 458-74.
7. Central Vein Occlusion Study Group. Baseline and early natural history report: the Central Vein Occlusion Study. Arch Ophthalmol 1993; 111: 1087-95.
8. Hayreh SS, Klugman MR, Beri M, Kimura AE, Podhajsky P. Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase. Graefes Arch Clin Exp Ophthalmol 1990; 228: 201-17.
9. Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997; 115: 486-91.
10. McAllister IL, Gillies M, Smithies L etal. The Central Retinal Vein Bypass Study: a trial of laser-induced chorioretinal venous anastomosis for central retinal vein occlusion. Ophthamology 2010; 117: 954-65.
11. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM. Prognostic factors for retinal vein occlusion: a prospective study of 175 cases. Ophthalmology 1996; 103: 551-60.
12. Green WR, Chan CC, Hutchins GM, Terry JM. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc 1981; 79: 371-442.
13. Taylor AW, Sehu W, Williamson TH, Lee WR. Morphometric assessment of the central retinal artery and vein in the optic nerve head. Can J Ophthalmol 1993; 28: 320-4.
14. Williamson TH. A 'throttle' mechanism in the central retinal vein in the region of the lamina cribrosa. Br J Ophthalmol 2007; 91: 1190-3.
15. Kang MH, Balaratnasingam C, Yu PK etal. Morphometric characteristics of central retinal artery and vein endothelium in the normal human optic nerve head. Invest Ophthalmol Vis Sci 2011; 52: 1359-67.
16. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2005; 24: 493-519.
17. Beaumont PE, Kang HK. Pattern of vascular nonperfusion in retinal venous occlusions occurring within the optic nerve with and without optic nerve head swelling. Arch Ophthalmol 2000; 118: 1357-63.
18. Rath EZ, Frank RN, Shin DH, Kim C. Risk factors for retinal vein occlusions: a case-control study. Ophthalmology 1992; 99: 509-14.
19. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996; 114: 545-54.
20. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia: The Blue Mountains Eye Study. Arch Ophthalmol 1996; 114: 1243-7.
21. Koizumi H, Ferrara DC, Brué C, Spaide RF. Central retinal vein occlusion case-control study. Am J Ophthalmol 2007; 144: 858-63.
22. Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001; 131: 61-77.
23. Cheung N, Klein R, Wang JJ etal. Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Invest Ophthalmol Vis Sci 2008; 49: 4297-302.
24. Browning DJ, Fraser CM. Retinal vein occlusions in patients taking warfarin. Ophthalmology 2004; 111: 1196-200.
25. Mruthyunjaya P, Wirostko WJ, Chandrashekhar R etal. Central retinal vein occlusion in patients treated with long-term warfarin sodium (coumadin) for anticoagulation. Retina 2006; 26: 285-91.
26. Nash GB. Blood rheology and ischaemia. Eye 1991; 5: 151-8.
27. Ring CP, Pearson TC, Sanders MD, Wetherley-Mein G. Viscosity and retinal vein thrombosis. Br J Ophthalmol 1976; 60: 397-410.
28. Trope GE, Lowe GD, McArdle BM etal. Abnormal blood viscosity and haemostasis in long-standing retinal vein occlusion. Br J Ophthalmol 1983; 67: 137-42.
29. Williamson TH, Rumley A, Lowe GD. Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol 1996; 80: 203-8.
30. Arend O, Remky A, Jung F, Kiesewetter H, Reim M, Wolf S. Role of rheologic factors in patients with acute central retinal vein occlusion. Ophthalmology 1996; 103: 80-6.
31. Glacet-Bernard A, Chabanel A, Lelong F, Samama MM, Coscas G. Elevated erythrocyte aggregation in patients with central retinal vein occlusion and without conventional risk factors. Ophthalmology 1994; 101: 1483-7.
32. Sofi F, Mannini L, Marcucci R etal. Role of haemorheological factors in patients with retinal vein occlusion. Thromb Haemost 2007; 98: 1215-19.
33. Francis PJ, Stanford MR, Graham EM. Dehydration is a risk factor for central retinal vein occlusion in young patients. Acta Ophthalmol Scand 2003; 81: 415-16.
34. Chua B, Kifley A, Wong TY, Mitchell P. Homocysteine and retinal vein occlusion: a population-based study. Am J Ophthalmol 2005; 139: 181-2.
35. Vine AK. Hyperhomocysteinemia: a risk factor for central retinal vein occlusion. Am J Ophthalmol 2000; 129: 640-4.
36. Brown BA, Marx JL, Ward TP etal. Homocysteine: a risk factor for retinal venous occlusive disease. Ophthalmology 2002; 109: 287-90.
37. Weger M, Stanger O, Deutschmann H etal. Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002; 240: 286-90.
38. Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol 2003; 136: 1136-50.
39. Pinna A, Carru C, Zinellu A, Dore S, Deiana L, Carta F. Plasma homocysteine and cysteine levels in retinal vein occlusion. Invest Ophthalmol Vis Sci 2006; 47: 4067-71.
40. McGimpsey SJ, Woodside JV, Cardwell C, Cahill M, Chakravarthy U. Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: a meta-analysis. Ophthalmology 2009; 116: 1778-87.
41. Cobo-Soriano R, Sánchez-Ramón S, Aparicio MJ etal. Antiphospholipid antibodies and retinal thrombosis in patients without risk factors: a prospective case-control study. Am J Ophthalmol 1999; 128: 725-32.
42. Bashshur ZF, Taher A, Masri AF, Najjar D, Arayssi TK, Noureddin BN. Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors: a prospective study. Retina 2003; 23: 486-90.
43. Ilhan F, Celiker U, Godekmerdan A, Kan E. The antiphospholipid antibody syndrome research in patients with retinal venous occlusion. Arch Med Res 2005; 36: 372-5.
44. Di Capua M, Coppola A, Albisinni R etal. Cardiovascular risk factors and outcome in patients with retinal vein occlusion. J Thromb Thrombolysis 2010; 30: 16-22.
45. Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Throm Haemost 2005; 93: 1021-6.
46. Fegan CD. Central retina vein occlusion and thrombophilia. Eye 2002; 16: 98-106.
47. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology 1995; 102: 1434-44.
48. Leoncini G, Bruzzese D, Signorello MG etal. Platelet activation by collagen is increased in retinal vein occlusion. Throm Haemost 2007; 97: 218-27.
49. Yamamoto T, Kamei M, Yokoi N, Yasuhara T, Tei M, Kinoshita S. Comparative effect of antiplatelet therapy in retinal vein occlusion evaluated by the particle-counting method using light scattering. Am J Ophthalmol 2004; 138: 809-17.
50. Arroyo JG, Dastgheib K, Hatchell DL. Antithrombotic effect of ticlopidine in an experimental model of retinal vein occlusion. Jpn J Ophthalmol 2001; 45: 359-62.
51. Kohner EM, Hamilton AM, Bulpitt CJ, Dollery CT. Streptokinase in the treatment of central retinal vein occlusion: a controlled trial. Trans Ophthalmol Soc UK 1974; 94: 599-603.
52. Kohner EM, Pettit JE, Hamilton AM, Bulpitt CJ, Dollery CT. Streptokinase in central retinal vein occlusion: a controlled clinical trial. BMJ 1976; 1: 550-3.
53. Elman MJ. Thrombolytic therapy for central retinal vein occlusion: results of a pilot study. Trans Am Ophthalmol Soc 1996; 94: 471-504.
54. Lahey JM, Fong DS, Kearney J. Intravitreal tissue plasminogen activator for acute central retinal vein occlusion. Ophthalmic Surg Lasers 1999; 30: 427-34.
55. Glacet-Bernard A, Kuhn D, Vine AK, Oubraham H, Coscas G, Soubrane G. Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study. Br J Ophthalmol 2000; 84: 609-13.
56. Weiss JN, Bynoe LA. Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. Ophthalmology 2001; 108: 2249-57.
57. Bynoe LA, Hutchins RK, Lazarus HS, Friedberg MA. Retinal endovascular surgery for central retinal vein occlusion: initial experience of four surgeons. Retina 2005; 25: 625-32.
58. Vasco-Posada J. Modification of the circulation in the posterior pole of the eye. Ann Ophthalmol 1972; 4: 48-59.
59. Dev S, Buckley EG. Optic nerve sheath decompression for progressive central retinal vein occlusion. Ophthalmic Surg Lasers 1999; 30: 181-4.
60. Rodríguez A, Rodríguez FJ, Betancourt F. Presumed occlusion of posterior ciliary arteries following central retinal vein decompression surgery. Arch Ophthalmol 1994; 112: 54-6.
61. Opremcak EM, Bruce RA, Lomeo MD, Ridenour CD, Letson AD, Rehmar AJ. Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases. Retina 2001; 21: 408-15.
62. Opremcak EM, Rehmar AJ, Ridenour CD, Kurz DE. Radial optic neurotomy for central retinal vein occlusion: 117 consecutive cases. Retina 2006; 26: 297-305.
63. Hasselbach HC, Ruefer F, Feltgen N etal. Treatment of central retinal vein occlusion by radial optic neurotomy in 107 cases. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1145-56.
64. Weizer JS, Stinnett SS, Fekrat S. Radial optic neurotomy as treatment for central retinal vein occlusion. Am J Ophthalmol 2003; 136: 814-19.
65. Martínez-Jardón CS, Meza-de Regil A, Dalma-Weiszhausz J etal. Radial optic neurotomy for ischaemic central vein occlusion. Br J Ophthalmol 2005; 89: 558-61.
66. Horio N, Horiguchi M. Retinal blood flow and macular edema after radial optic neurotomy for central retinal vein occlusion. Am J Ophthalmol 2006; 141: 31-4.
67. Hayreh SS. Radial optic neurotomy for central retinal vein occlusion [letter]. Retina 2002; 22: 374-7.
68. Garcia-Arumi J, Boixadera A, Martinez-Castillo V, Castillo R, Dou A, Corcostegui B. Chorioretinal anastomosis after radial optic neurotomy for central retinal vein occlusion. Arch Ophthalmol 2003; 121: 1385-91.
69. Nomoto H, Shiraga F, Yamaji H etal. Evaluation of radial optic neurotomy for central retinal vein occlusion by indocyanine green videoangiography and image analysis. Am J Ophthalmol 2004; 138: 612-19.
70. Williamson TH, Poon W, Whitefield L, Strothoudis N, Jaycock P. A pilot study of pars plana vitrectomy, intraocular gas, and radial neurotomy in ischaemic central retinal vein occlusion. Br J Ophthalmol 2003; 87: 1126-9.
71. Schneider U, Inhoffen W, Grisanti S, Bartz-Schmidt KU. Characteristics of visual field defects by scanning laser ophthalmoscope microperimetry after radial optic neurotomy for central retinal vein occlusion. Retina 2005; 25: 704-12.
72. Tsujikawa A, Hangai M, Kikuchi M, Ishida K, Kurimoto Y. Visual field defect after radial optic neurotomy for central retinal vein occlusion. Jpn J Ophthalmol 2006; 50: 158-60.
73. Yamamoto S, Takatsuna Y, Sato E, Mizunoya S. Central retinal artery occlusion after radial optic neurotomy in a patient with central retinal vein occlusion. Am J Ophthalmol 2005; 139: 206-7.
74. Takaya K, Suzuki Y, Nakazawa M. Massive hemorrhagic retinal detachment during radial optic neurotomy. Graefes Arch Clin Exp Ophthalmol 2006; 244: 265-7.
75. Strauss RW, Priglinger SG, Alge CS, Grueterich M, Haritoglou C. Persistent serous retinal detachment after radial optic neurotomy [letter]. Clin Experiment Ophthalmol 2006; 34: 718-20.
76. McAllister IL, Constable IJ. Laser-induced chorioretinal venous anastomosis for treatment of nonischemic central retinal vein occlusion. Arch Ophthalmol 1995; 113: 456-62.
77. McAllister IL, Douglas JP, Constable IJ, Yu DY. Laser-induced chorioretinal venous anastomosis for nonischemic central retinal vein occlusion: evaluation of the complications and their risk factors. Am J Ophthalmol 1998; 126: 219-29.
78. Fong CS, Barry C, McAllister IL. Intravitreal bevacizumab (Avastin) as a treatment of the neovascular complications of laser-induced chorioretinal anastomosis for nonischaemic central retinal vein occlusion. Clin Experiment Ophthalmol 2009; 37: 485-89.
79. Tsui I, Kaines A, Havunjian MA etal. Ischaemic index and neovascularisation in central retinal vein occlusion. Retina 2011; 31: 105-10.
80. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: the Central Vein Occlusion Study Group M report. Ophthalmology 1995; 102: 1425-33.
81. Hansen LL, Danisevskis P, Arntz HR, Hovener G, Wiederholt M. A randomised prospective study on treatment of central retinal vein occlusion by isovolaemic haemodilution and photocoagulation. Br J Ophthalmol 1985; 69: 108-16.
82. Hanson LL, Wiek J, Wiederholt M. A randomised prospective study of treatment of non-ischaemic central retinal vein occlusion by isovolaemic haemodilution. Br J Ophthalmol 1989; 73: 895-9.
83. Luckie AP, Wroblewski JJ, Hamilton P etal. A randomised prospective study of outpatient haemodilution for central retinal vein obstruction. Aust NZ J Ophthalmol 1996; 24: 223-32.
84. Glacet-Bernard A, Atassi M, Fardeau C etal. Hemodilution therapy using automated erythrocytapheresis in central retinal vein occlusion: results of a multicenter randomized controlled study. Graefes Arch Clin Exp Ophthalmol 2011; 249: 505-12.
85. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama M. A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin. Am J Ophthalmol 1994; 118: 421-9.
86. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992; 110: 1155-9.
87. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998; 341: 309-15.
88. McAllister IL, Vijayasekaran S, Chen SD, Yu DY. Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. Am J Ophthalmol 2009; 147: 838-46.
89. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127: 1101-14.
90. Ramchandran RS, Fekrat S, Stinnett SS, Jaffe GJ. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results. Am J Ophthalmol 2008; 146: 285-91.
91. Haller JA, Bandello F, Belfort R etal. For the OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-46.
92. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998; 105: 412-16.
93. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36: 336-9.
94. Iturralde D, Spaide RF, Meyerle CB. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006; 26: 279-84.
95. Costa RA, Jorge R, Calucci D, Melo LA, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007; 27: 141-9.
96. Wroblewski JJ, Wells JA, Adamis AP etal. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol 2009; 127: 374-80.
97. Brown DM, Campochiaro PA, Singh RP etal. For the CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1124-33.
98. Campochiaro PA, Brown DM, Awh CC etal. Sustained benefits from Ranibizumab for macular edema following central retinal vein occlusion: twelve month outcomes of a phase III study. Ophthalmology 2011; 118: 2041-9.